Fig 1: mRNA expression of the GLP-1 precursor proglucagon after ISS treatment for 1 h. (A) The expression of proglucagon increased against increasing doses of ISS Significance was determined by an unpaired t-test (one-tailed), *** p < 0.001, * p < 0.05 vs. NT. (B) The mRNA expression of proglucagon was significantly decreased in ISS-treated NCI-H716 cells with siRNA-mediated knockdown of GNAT3 and hTAS2R50. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s multiple comparison test. Values are expressed as the mean ± SEM; *** p < 0.001, * p < 0.05 vs. NT, ### p < 0.001, vs. siRNA control, n = 6.
Fig 2: ISS-induced GLP-1 secretion in NCI-H716 cells. (A) Secretion of GLP-1 from ISS-treated NCI-H716 cells against increasing doses of ISS. Significance was determined by an unpaired t-test (one-tailed), *** p < 0.001 vs. NT. (B) siRNA-mediated decrease in GLP-1 secretion. Statistical analysis was conducted by one-way ANOVA with Bonferroni’s multiple comparison test, *** p < 0.001 vs. NT, **** p < 0.0001 vs. NT, ### p < 0.001 vs. siRNA control. (C) IP3R inhibitor (D) Inhibition of PLC-dependent processes. Significance was determined by an unpaired t-test (one-tailed), *** p < 0.001 vs. NT, ### p < 0.001 vs. vehicle. Values are expressed as the mean ± SEM, n = 4.
Supplier Page from Abcam for Human GLP1 (7-36) ELISA Kit